Aier Eye Hospital: From a Small Hospital in Changsha to a Global Ophthalmic Chain Leader via Hierarchical Chains and M&A Funds

Origin

Chen Bang engaged in medical equipment leasing in his early years and noticed that public ophthalmic resources were scarce with severe waiting queues. In 1997, in Changsha, he co-built a cataract treatment center with a public hospital through equipment collaboration, using small funds to validate demand, and after proving the model, shifted to self-built chains. In 2009, when it went public on the ChiNext board, Aier had only 19 hospitals nationwide with 630,000 annual outpatient visits (according to the prospectus); by the end of 2025, it had expanded to 842 ophthalmic medical institutions, with overseas revenue reaching 8 billion RMB (disclosed by the company).

Milestones

Turning Points

• Shifted from equipment cooperation to self-built hospitals, establishing the starting point for chain replication
• ChiNext listing opened capital market financing channels, making national expansion possible
• M&A fund external incubation model resolved expansion capital pressure while burying goodwill risks
• Post-surge market capitalization vaporization of 300 billion forced Aier to re-examine the balance between high growth and internal control
• Hong Kong listing became a new pivot for globalization while exposing structural dilemmas in compliance and goodwill

Failures & Pitfalls

• Excessively rapid expansion led to an increase in medical quality disputes across some hospitals, damaging brand trust
• M&A fund model accumulated nearly 10 billion RMB in off-balance-sheet goodwill, facing concentrated impairment risks
• Retroactive tax payment of 524 million RMB revealed shortcomings in financial and tax compliance, dragging down the Hong Kong listing process
• The founder's involvement in the psychiatric hospital insurance fraud controversy caused reputational risk spillover
• Overseas M&A integration fell short of expectations, with high localized operating costs

Core Data

• 海外营收：8 billion RMB (publicly available information, independent verification pending)
• 市值较历史高点蒸发：300 billion RMB (publicly available information, independent verification pending)
• 创始人身家缩水：114.5 billion RMB (publicly available information, independent verification pending)
• 补税金额：524 million RMB (publicly available information, independent verification pending)
• 商誉规模：Nearly 10 billion RMB (publicly available information, independent verification pending)
• 医院及门诊总数：Over 1,000 (publicly available information, independent verification pending)

Competitors / Peers

In China's private ophthalmology market, Aier Eye Hospital is the absolute leader, primarily benchmarking against listed companies such as Huaxia Eye Hospital,普瑞眼科 (Pure Ophthalmics / Purui Eye Hospital), Hushi Eye Hospital, and Guangzheng Eye Hospital. Huaxia Eye Hospital deeply cultivates Fujian and East China; Purui Eye Hospital focuses mainly on multi-city single-store centers; Hushi Eye Hospital holds firm to the Northeast region; and Guangzheng Eye Hospital expands rapidly through M&A. Internationally, through acquisitions of European and Southeast Asian ophthalmic institutions, Aier competes directly with local chain brands. Competitors' scales are far smaller than Aier's, but medical services possess strong localized attributes. Aier's true moats are its hierarchical chain network and capital strength, while its greatest vulnerabilities are goodwill and compliance management.